The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells

Published:2013-08-06 Issue:287 Volume:6 Page:
ISSN:1945-0877
Container-title:Science Signaling
language:en
Short-container-title:Sci. Signal.

Author:

Meyer Aaron S.¹²,Miller Miles A.¹,Gertler Frank B.²³,Lauffenburger Douglas A.¹²³

Affiliation:

1. Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

2. David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

3. Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

Abstract

Amplification of downstream signaling by AXL receptor tyrosine kinase alters the migratory response of breast cancer cells.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference62 articles.

1. The ERBB network: at last, cancer therapy meets systems biology

2. ERBB receptors and cancer: the complexity of targeted inhibitors

3. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

4. Rescue Screens with Secreted Proteins Reveal Compensatory Potential of Receptor Tyrosine Kinases in Driving Cancer Growth

5. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

Cited by 235 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

2. A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib;Cell Reports Medicine;2024-08

3. Exploring the multifaceted role of obesity in breast cancer progression;Frontiers in Cell and Developmental Biology;2024-07-08

4. A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer;Oral Oncology;2024-07

5. AXL receptor as an emerging molecular target in colorectal cancer;Drug Discovery Today;2024-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3